ADMA Biologics Inc (ADMA): Does It Stack Up To Its Peers?

Judging by the fact that ADMA Biologics Inc (NASDAQ:ADMA) has weathered bearish sentiment from the aggregate hedge fund industry, it’s easy to see that there exists a select few money managers who were dropping their entire stakes last quarter. It’s worth mentioning that Hal Mintz’s Sabby Capital dropped the biggest position of the “upper crust” of funds studied by Insider Monkey, valued at about $0.6 million in stock. Efrem Kamen’s fund, Pura Vida Investments, also dumped its stock, about $0.2 million worth.

Let’s now review hedge fund activity in other stocks similar to ADMA Biologics Inc (NASDAQ:ADMA). We will take a look at Harvard Bioscience, Inc. (NASDAQ:HBIO), Xcel Brands Inc (NASDAQ:XELB), FBR & Co (NASDAQ:FBRC), and Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX). This group of stocks’ market caps resemble ADMA’s market cap.

As you can see these stocks had an average of 5 hedge funds with bullish positions and the average amount invested in these stocks was $10 million. That figure was $50 million in ADMA’s case. Harvard Bioscience, Inc. (NASDAQ:HBIO) is the most popular stock in this table. On the other hand Xcel Brands Inc (NASDAQ:XELB) is the least popular one with only 3 bullish hedge fund positions. ADMA Biologics Inc (NASDAQ:ADMA) is tied as the most popular stock in this group and has a lot more invested in it than the other stocks. This is a positive signal, as we’d rather spend our time researching stocks that hedge funds are pouring money into. In this regard ADMA might be a good candidate to consider taking a long position in.

Disclosure: None